α-MSH is a remarkably versatile 13-amino acid neuropeptide cleaved from POMC. Far more than a pigmentation hormone, it regulates skin color and UV defense, suppresses appetite and controls body weight, modulates both innate and adaptive immunity, dampens inflammation across multiple organ systems, acts as the brain's own antipyretic to limit fever, drives memory, sexual behavior, and neuroprotection in the CNS, protects the heart from hypertrophy and ischemic injury, and maintains skin homeostasis across melanocytes, keratinocytes, fibroblasts, and endothelial cells.
Click a function below to jump directly to its explanation and references. The larger diagram is available below without taking over the first screen.
Click any box to jump to the full explanation below.
Each section below corresponds to a function in the diagram above. References are listed at the bottom of each section.
Pigmentation signaling cascade: UV trigger to melanin production via cAMP / MITF / tyrosinase
As an acute physiological response to UV radiation, keratinocytes produce and secrete α-MSH. The skin therefore does not wait passively for pituitary α-MSH — it generates its own local supply in response to damage, creating a paracrine loop that activates neighboring melanocytes immediately.
α-MSH binds the melanocortin-1 receptor (MC1R), a G protein-coupled receptor on melanocytes. After binding, the Gαs subunit dissociates from MC1R and stimulates adenylyl cyclase, generating cAMP. cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP Response Element Binding Protein). CREB then binds CRE-containing gene promoters to drive transcription.
Phosphorylated CREB drives the transcription of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte identity. MITF upregulates the three key melanogenic enzymes — tyrosinase (TYR), TYRP1, and TYRP2/DCT — which catalyze the sequential conversion of tyrosine into melanin. MITF also controls melanosome distribution by regulating RAB27A, the GTPase that anchors melanosomes to myosin motors for dendritic transport toward keratinocytes.
α-MSH promotes a switch from red/yellow pheomelanin to brown/black eumelanin. Both types share the same pathway up to dopaquinone. In eumelanogenesis, TYR, TRP1, and TRP2 continue the reaction to form brown/black pigment. In pheomelanogenesis, dopaquinone reacts with sulfhydryl groups to form cysteinyl-DOPA and then benzothiazine polymers — the red/yellow pigment. The ratio depends on the balance between α-MSH (favors eumelanin) and agouti signaling protein ASIP (favors pheomelanin) competing at MC1R.
Agouti signaling protein (ASIP) is the endogenous inverse agonist of MC1R. When ASIP occupies MC1R, cAMP does not rise, MITF is not upregulated, and the melanocyte defaults to pheomelanin. This molecular competition underlies coat color patterning in mammals and contributes to the red hair/fair skin phenotype in humans carrying loss-of-function MC1R variants.
Fully melanized melanosomes are transported along melanocyte dendrites and transferred to surrounding keratinocytes by cytocrine secretion. The symbiotic relationship between a melanocyte and its associated pool of keratinocytes is called the epidermal melanin unit (EMU). Melanin is then distributed within the epidermis, providing tanning and UV protection to a far larger cell population than the melanocytes alone.
MC1R has measurable constitutive (ligand-independent) activity, enhanced by α-MSH binding. Recent work has shown that UV and α-MSH trigger cilium formation in melanocytes. MC1R enters the primary cilium upon stimulation, generating sustained cAMP signaling and activating Sox9 as a transcriptional cofactor for MITF — a newly discovered mechanism that may explain why some MC1R variants impair pigmentation even when they retain basic cAMP signaling capacity.
Hypothalamic melanocortin appetite circuit: POMC vs AgRP/NPY competition at MC4R
The arcuate nucleus of the hypothalamus contains two opposing neuronal populations. POMC neurons release α-MSH and inhibit feeding; AgRP/NPY neurons promote feeding and are the natural antagonists. These two populations project to many of the same downstream targets — including the paraventricular nucleus (PVN) — where α-MSH and AgRP compete for MC4R binding to determine food intake and energy expenditure.
Leptin — released by adipose tissue in proportion to fat stores — binds receptors on POMC neurons in the arcuate nucleus, stimulating α-MSH release. Serotonin (5-HT) also activates POMC neurons. In contrast, ghrelin (the hunger hormone from the stomach) activates AgRP/NPY neurons, which suppress POMC neuron activity through NPY and GABA, thereby reducing α-MSH output and increasing hunger.
When α-MSH binds MC4R in the paraventricular nucleus, it triggers anorexigenic signals that create the perception of satiety. MC4R activation also increases energy expenditure by stimulating thyrotropin-releasing hormone (TRH) and activating the sympathetic nervous system. Loss-of-function MC4R mutations — the most common cause of monogenic obesity in humans — prevent children from experiencing satiety, causing severe hyperphagia and early-onset obesity.
AgRP is an endogenous inverse agonist at MC3R and MC4R. It directly blocks α-MSH binding and is itself upregulated by fasting and ghrelin. The ratio of α-MSH to AgRP tone at hypothalamic MC4R neurons is essentially the molecular tug-of-war that determines whether an organism feels hungry or full at any given moment.
The nucleus of the solitary tract (NTS) in the brainstem also expresses POMC neurons that can be activated by leptin, cholecystokinin (CCK), and other satiety signals arriving from the gut via the vagus nerve. α-MSH released in the NTS acutely reduces meal size and food intake. Overexpression of POMC in the NTS produces sustained anorexia — distinct from the transient effects seen with hypothalamic overexpression — because the NTS lacks compensatory AgRP expression.
α-MSH also acts within the ventral tegmental area (VTA) via MC3R to modulate dopamine release in the nucleus accumbens, influencing the reward value and hedonic appeal of food. This connects α-MSH to non-homeostatic (pleasure-driven) eating, not just hunger-driven intake.
alpha-MSH acts simultaneously on macrophages, T cells, and neutrophils to suppress inflammation and promote tolerance
The immunomodulating capacity of α-MSH is primarily driven by its effects on MC1R-expressing monocytes, macrophages, and dendritic cells (DCs). α-MSH down-regulates production of pro-inflammatory cytokines — including IL-1, IL-6, TNF-α, IL-2, IFN-γ, IL-4, and IL-13 — as well as costimulatory molecules (CD86, CD40, ICAM-1) on antigen-presenting DCs. Simultaneously, it upregulates IL-10, a key immunosuppressive cytokine.
α-MSH promotes the alternative (M2) activation of macrophages by inducing IL-10 and TGF-β production. M2 macrophages are anti-inflammatory and tissue-repairing, whereas M1 macrophages are pro-inflammatory. This polarization shift helps resolve rather than amplify immune responses.
α-MSH suppresses the activation of effector T cells and actively induces regulatory T cells (Tregs). This has been studied in detail in the ocular immune privilege system, where constitutively present α-MSH in the aqueous humor continuously suppresses T cell activation. The melanocortin pathway can convert a systemic effector T cell response into a regulatory one specific to local autoantigens — a process relevant to autoimmune disease management.
α-MSH induces MC1R expression and POMC transcription in monocytes, establishing an autocrine loop: α-MSH promotes more α-MSH production in immune cells, sustaining immunosuppression. Serum levels of α-MSH also increase during the acute phase of inflammation, suggesting it rises as a natural counter-regulatory signal.
In vivo, systemic and topical application of α-MSH (or its active C-terminal tripeptide KPV) inhibits both sensitization and elicitation phases of contact hypersensitivity reactions, and induces antigen-specific tolerance mediated by CTLA4+ and IL-10-producing T lymphocytes.
alpha-MSH anti-inflammatory pathway: dual NF-kB/p38 blockade and simultaneous IL-10 upregulation
α-MSH binds MC1R and MC3R on immune and stromal cells. This activates adenylyl cyclase via Gαs, raising intracellular cAMP, which activates PKA and phosphorylates CREB — upregulating anti-inflammatory gene expression. cAMP accumulation is central to most immunomodulatory effects of α-MSH.
The most important molecular mechanism is suppression of NF-κB activation. NF-κB is the master transcription factor for pro-inflammatory gene expression. α-MSH blocks nuclear translocation of NF-κB in macrophages, dendritic cells, neutrophils, keratinocytes, and fibroblasts — across different inflammatory triggers including LPS, IL-1β, and TNF-α.
α-MSH also suppresses p38 MAPK phosphorylation, a key stress kinase involved in cytokine production, cell adhesion, and neutrophil survival. Together with NF-κB inhibition, this provides a two-pronged block on the intracellular signaling that drives acute inflammation.
α-MSH suppresses production of TNF-α, IL-6, and IL-1, and inhibits chemokines that guide macrophage and neutrophil migration to inflammatory sites. It also inhibits nitric oxide (NO) synthesis by endotoxin-stimulated macrophages and neutrophils, and reduces prostaglandin E synthesis in fibroblasts. Meanwhile, IL-10 is upregulated — shifting the cytokine balance toward resolution.
α-MSH directly inhibits neutrophil migration toward chemoattractants such as FMLP and IL-8. This inhibition is mediated through cAMP accumulation in neutrophils and represents a key mechanism by which α-MSH limits influx of damaging immune cells to inflamed tissues.
α-MSH acting within the brain can inhibit peripheral inflammation through descending neurogenic pathways dependent on peripheral β2-adrenergic receptors. The brain can therefore modulate tissue inflammation systemically — not just through circulating hormones — making α-MSH mechanistically distinct from conventional anti-inflammatory drugs.
alpha-MSH acts upstream of PGE2 as an endogenous brake on the fever cascade
Fever follows a well-defined cascade: invading pathogens release endotoxin → macrophages produce pyrogenic cytokines (IL-1β, TNF-α, IL-6) → these cytokines reach the brain's blood-brain border where they trigger prostaglandin E2 (PGE2) synthesis → PGE2 penetrates the blood-brain barrier and raises the preoptic area (POA) temperature set-point → the body shivers and vasoconstricts to reach that higher set-point.
The concentration of α-MSH in the septal region of the brain increases during fever. This rise is a physiological response to the febrile stimulus — the brain deploying its own antipyretic in proportion to the inflammatory challenge. α-MSH is synthesized largely within arcuate nucleus neurons, with projections to the septum and limbic areas positioned to modulate the fever response.
When antiserum against α-MSH was injected into the third cerebral ventricle of rabbits, fever induced by IL-1 was significantly prolonged and the temperature rise was greater. Neutralizing endogenous α-MSH made fever worse — direct evidence that α-MSH is a physiologically active antipyretic. Critically, the antiserum did not alter normal (afebrile) body temperature, confirming selectivity for the febrile state.
α-MSH attenuates both the rise in body temperature and the rise in plasma PGE2 levels induced by LPS, endogenous pyrogen, TNF-α, and IL-1β. When PGE2 was injected directly into the brain ventricle — bypassing the cytokine cascade — α-MSH had no effect on the temperature rise. This proves α-MSH acts upstream of PGE2, suppressing cytokine-driven PGE2 synthesis rather than blocking PGE2's direct action on hypothalamic thermosensitive neurons.
α-MSH reduces fever at doses that do not affect normal (afebrile) body temperature — distinguishing it from drugs that can cause hypothermia. It lowers the threshold for cold thermogenesis during fever, telling the body's thermostat to tolerate a lower temperature again, without pulling the set-point below baseline.
α-MSH also attenuates IL-1-induced excess non-REM sleep that accompanies fever. The thermoregulatory and sleep-regulatory consequences of fever are co-regulated by the melanocortin system — α-MSH opposes both the temperature elevation and the behavioral changes of the sickness response simultaneously.
MC4R — the primary CNS melanocortin receptor — is expressed broadly across the cortex, thalamus, hypothalamus, amygdala, brainstem, and spinal cord. MC3R has more restricted expression in the hypothalamus, thalamus, VTA, raphe nucleus, and hippocampus.
alpha-MSH CNS roles organized by brain region and behavioral output
α-MSH enhances memory and learning through multiple mechanisms: upregulation of CREB phosphorylation, induction of brain-derived neurotrophic factor (BDNF), promotion of neurogenesis, increased viability of hippocampal pyramidal cells, and stimulation of neurite outgrowth. In Alzheimer's disease mouse models, synthetic α-MSH analogs improved spatial memory and rescued GABAergic interneuron loss in the hippocampus. α-MSH levels are reduced in the brain and CSF of Alzheimer's patients, and α-MSH autoantibody levels correlate with cognitive dysfunction.
Microinjections of α-MSH into the paraventricular nucleus of the hypothalamus induce penile erection, stretching, and yawning — collectively called the melanocortin erectile response. MC4R in the hypothalamus and spinal cord mediates these effects. Synthetic α-MSH analogs (including Melanotan II and bremelanotide/PT-141) have been investigated and developed for psychogenic erectile dysfunction and hypoactive sexual desire disorder (bremelanotide was FDA-approved in 2019 for HSDD).
Intra-VTA injection of α-MSH increases dopamine and DOPAC levels in the nucleus accumbens via MC3R activation. α-MSH also increases the firing rate of MC3R-expressing VTA neurons, linking the melanocortin system to the mesolimbic reward circuit and influencing hedonic feeding, motivation, and reward-driven behavior beyond simple homeostatic hunger.
Both intraventricular and VTA microinjections of α-MSH produce excessive grooming and significantly increased locomotor activity. These stereotyped behaviors are among the most reliably observed behavioral signatures of central melanocortin activation.
In models of cerebral ischemia, traumatic brain injury (TBI), and neurodegenerative disease, α-MSH and its analogs reduce neuronal loss, inhibit apoptotic cascades, and improve functional recovery. After TBI, MC1R levels in the brain increase three-fold within 12 hours. A single dose of the α-MSH fragment α-MSH(11–13) significantly reduced lesion volume, inflammatory markers (TNF-α, IL-1β), and microglial activation. In stroke models, α-MSH abolished intracerebral TNF-α and IL-1β gene expression after arterial occlusion and reperfusion.
Within the CNS, α-MSH modulates microglial activation and acts as an autocrine anti-inflammatory factor in microglia. MC4R activation in astrocytes reduces the inflammatory response and prevents apoptosis induced by LPS and IFN-γ — positioning α-MSH as a potential therapeutic target in neuroinflammatory and neurodegenerative disorders.
alpha-MSH cardiac effects via MC5R: anti-hypertrophic, ischemia protection, and HO-1-mediated vasodilation
α-MSH is expressed in the heart — particularly in the ventricles — where it acts locally via MC5R on cardiomyocytes. Plasma α-MSH levels are elevated in patients with hypertrophic or dilated cardiomyopathy, suggesting it rises as a compensatory response to cardiac stress. Conversely, α-MSH production is significantly reduced in the failing heart.
Pharmacological activation of MC5R improved systolic function and reduced cardiac fibrosis in pressure-overloaded mice. Silencing MC5R in cardiomyocytes induced hypertrophy and fibrosis markers in vitro and aggravated cardiac hypertrophy in vivo. α-MSH acts as a brake on the maladaptive remodeling — pathological cell growth and scarring — that leads progressively to heart failure.
Treatment with melanocortin analogs during coronary artery occlusion upregulated cardioprotective transcription factors (pJAK2, pERK1/2, pTyr-STAT3), reduced inflammatory mediators (TNF-α, pJNK), increased pro-survival proteins (HO-1, Bcl-XL), and decreased both ventricular arrhythmias and infarct size. The reduction in reperfusion-induced ventricular fibrillation corresponded to reduced apoptotic cell death.
α-MSH induces vasodilation through activation of HO-1, a heat shock protein and major antioxidant defense molecule. HO-1 produces carbon monoxide and biliverdin — both of which have vasodilatory and cytoprotective properties. Blocking HO-1 abolishes the cardioprotective effects of α-MSH, confirming this pathway is essential to its mechanism.
α-MSH influences sympathetic activation in the cardiovascular system, affecting systolic activity, heart rate, blood pressure, and coronary vascular responses. α-MSH levels during exercise recovery hold predictive value for heart rate recovery, suggesting a contributing role in cardiopulmonary performance and potential prognostic value in coronary artery disease.
alpha-MSH acts across all major skin cell types to coordinate UV defense, inflammation control, and tissue repair
In addition to driving melanin synthesis, α-MSH protects melanocytes from UV-induced oxidative stress independent of melanin production. Pre-treatment with α-MSH reduces UV-induced generation of 8-oxodG (a major form of oxidative DNA damage), increases protein levels of catalase and ferritin (antioxidant enzymes), and enhances overall DNA repair capacity — maintaining genomic stability in melanocytes over decades of UV exposure.
α-MSH enhances DNA repair in keratinocytes by a separate mechanism from melanin production. After binding MC1R on keratinocytes, it activates adenylyl cyclase → XAB1 → nuclear translocation of XPA, a critical factor in nucleotide excision repair (NER). Intracutaneous injection of MSH prevented UV-induced DNA damage in human and mouse skin independent of melanogenesis. α-MSH also prevents UVB-induced suppression of Nrf2, a key antioxidant transcription factor, in both keratinocytes and melanocytes.
α-MSH suppresses keratinocyte TLR2-mediated inflammatory responses induced by bacterial stimuli. It down-regulates TLR2 and IL-8 expression and blocks NF-κB nuclear translocation via an IRAK-M-dependent mechanism — regulating how keratinocytes respond to the skin microbiome and bacterial pathogens.
MC1R expressed by dermal fibroblasts mediates antifibrogenic effects of α-MSH. It regulates fibroblast cytokine production and collagenase production, preventing both excessive degradation and excessive scarring of the dermal extracellular matrix — helping maintain the structural integrity of the dermis.
α-MSH is involved in normal skin wound healing. Its anti-inflammatory properties have been demonstrated in cutaneous wound healing in vivo and in fibroblast models in vitro. Local α-MSH produced by keratinocytes and melanocytes in response to inflammatory stimuli likely contributes to resolving the inflammatory phase and promoting repair.
Pro-inflammatory cytokines and UV radiation induce epidermal cells — keratinocytes and melanocytes — to synthesize and release α-MSH themselves. The skin is therefore an active producer, creating a local paracrine loop that fine-tunes inflammation and repair in real time at the site of damage.
Systemic application of α-MSH inhibits both induction and elicitation of contact hypersensitivity reactions and induces hapten-specific tolerance — mediated by the generation of CTLA4+ and IL-10-producing T lymphocytes. Relevant to allergic contact dermatitis and related skin immune disorders.